Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Equities researchers at SVB Leerink decreased their Q2 2021 EPS estimates for shares of Amicus Therapeutics in a research report issued to clients and investors on Tuesday, May 11th. SVB Leerink analyst J. Schwartz now anticipates that the biopharmaceutical company will earn ($0.22) per share for the quarter, down from their prior estimate of ($0.21). SVB Leerink has a “Market Perform” rating and a $13.00 price objective on the stock. SVB Leerink also issued estimates for Amicus Therapeutics’ Q3 2021 earnings at ($0.23) EPS, Q4 2021 earnings at ($0.19) EPS, FY2021 earnings at ($0.89) EPS and FY2022 earnings at ($0.53) EPS.
Several other equities analysts also recently commented on the company. Stifel Nicolaus started coverage on Amicus Therapeutics in a research note on Monday, March 8th. They issued a “hold” rating and a $13.00 price objective on the stock. Robert W. Baird reiterated a “buy” rating on shares of Amicus Therapeutics in a research note on Wednesday, March 3rd. JPMorgan Chase & Co. downgraded Amicus Therapeutics from an “overweight” rating to a “neutral” rating and set a $19.00 price objective on the stock. in a research note on Friday, February 12th. Citigroup dropped their price objective on Amicus Therapeutics from $27.00 to $16.00 in a research note on Friday, February 12th. Finally, Cantor Fitzgerald upgraded Amicus Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Monday, April 19th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. Amicus Therapeutics currently has an average rating of “Hold” and an average target price of $20.31.
Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Sunday, May 9th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The business had revenue of $66.40 million during the quarter, compared to the consensus estimate of $71.76 million. Amicus Therapeutics had a negative net margin of 120.18% and a negative return on equity of 73.81%.
Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of Amicus Therapeutics by 4.3% in the fourth quarter. BlackRock Inc. now owns 21,877,442 shares of the biopharmaceutical company’s stock worth $505,149,000 after buying an additional 908,634 shares in the last quarter. Morgan Stanley raised its position in shares of Amicus Therapeutics by 14.6% in the fourth quarter. Morgan Stanley now owns 12,730,857 shares of the biopharmaceutical company’s stock worth $293,954,000 after buying an additional 1,617,072 shares in the last quarter. Lone Pine Capital LLC purchased a new stake in shares of Amicus Therapeutics in the fourth quarter worth $154,213,000. Jennison Associates LLC raised its position in shares of Amicus Therapeutics by 28.5% in the first quarter. Jennison Associates LLC now owns 5,733,479 shares of the biopharmaceutical company’s stock worth $56,647,000 after buying an additional 1,270,896 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Amicus Therapeutics by 7.8% in the first quarter. Geode Capital Management LLC now owns 4,375,227 shares of the biopharmaceutical company’s stock worth $43,227,000 after buying an additional 316,124 shares in the last quarter.
In related news, COO Bradley L. Campbell sold 10,514 shares of the stock in a transaction on Monday, May 3rd. The stock was sold at an average price of $10.27, for a total value of $107,978.78. Following the sale, the chief operating officer now owns 422,536 shares in the company, valued at $4,339,444.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John F. Crowley sold 7,682 shares of the stock in a transaction on Monday, March 22nd. The stock was sold at an average price of $10.29, for a total value of $79,047.78. Following the completion of the sale, the chief executive officer now owns 829,024 shares in the company, valued at approximately $8,530,656.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,393 shares of company stock worth $1,083,109. Company insiders own 2.50% of the company’s stock.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.